PA
IRWD icon

Parallel Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Parallel Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-199
Closed -$820 – 3573
2024
Q3 		$820 Buy
+199
New +$1.07K ﹤0.01% 3079
2024
Q2 		– Sell
-1,617
Closed -$14.1K – 3372
2024
Q1 		$14.1K Sell
1,617
-305
-16% -$3.7K ﹤0.01% 2157
2023
Q4 		$22K Buy
1,922
+778
+68% +$7.7K ﹤0.01% 1877
2023
Q3 		$11K Sell
1,144
-733
-39% -$7.18K ﹤0.01% 2147
2023
Q2 		$20K Buy
1,877
+192
+11% +$2.06K ﹤0.01% 1856
2023
Q1 		$17.7K Buy
1,685
+638
+61% +$7.15K ﹤0.01% 1892
2022
Q4 		$13K Buy
1,047
+138
+15% +$1.56K ﹤0.01% 1931
2022
Q3 		$9K Buy
909
+173
+24% +$1.96K ﹤0.01% 2042
2022
Q2 		$8K Buy
736
+677
+1,147% +$7.97K ﹤0.01% 2083
2022
Q1 		$1K Buy
+59
New +$676 ﹤0.01% 2767
2021
Q4 		– Sell
-22
Closed – – 3181
2021
Q3 		$0 Buy
+22
New +$284 ﹤0.01% 3165
2019
Q3 		– Sell
-108
Closed -$1K – 2442
2019
Q2 		$1K Buy
+108
New +$1.21K ﹤0.01% 2201

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Parallel Advisors's IRWD Position: Q4 2024 in Review

Parallel Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q4 2024, closing a stake of 199 shares — an estimated $820 sold.

Parallel Advisors first reported a position in IRWD in Q2 2019 and held it in 12 quarters. The position peaked at $22K in Q4 2023. 223 funds tracked by Wall St. Rank hold IRWD as of Q4 2024.

  • Parallel Advisors reported no remaining Ironwood Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Parallel Advisors sold 199 Ironwood Pharmaceuticals shares in Q4 2024, an estimated $820.
  • Parallel Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2019 and held it in 12 quarters.
  • Parallel Advisors's Ironwood Pharmaceuticals position peaked at $22K in Q4 2023.
  • 223 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q4 2024.

Based on Parallel Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.